Myeloma Investment Fund invests in Nammi Therapeutics

Advances Clinical Development of Lead Program, QXL138AM - MMRF

Nammi Therapeutics, Inc. (Nammi) announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round.

Nammi Therapeutics, Inc. Completes Series B Round with ...

(Nammi) announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round prior to the planned start ...

Myeloma Investment Fund invests in Nammi Therapeutics, Inc.'s ...

Jones Day advised Myeloma Investment Fund in $1 million investment in Nammi Therapeutics, Inc.'s Series B financing.

News and Updates From the Myeloma Investment Fund®

News · Opna Bio Doses First Patient in Phase 1 Study in Multiple Myeloma with OPN-6602, an EP300/CBP Bromodomain Inhibitor · Nammi Therapeutics, Inc. · Myeloma ...

Nammi Therapeutics Secures Series B Funding from MMRF's ...

The Myeloma Investment Fund (MIF) is a venture philanthropy fund dedicated to investing in promising oncology companies, clinical assets, and ...

Nammi Therapeutics, Inc. Announces First Patient Dosed with ...

PRNewswire/ -- Nammi Therapeutics, Inc. (Nammi), a ... (Nammi) announces a $1M investment commitment by the Myeloma Investment Fund ...

Nammi Therapeutics Completes Series B Funding - FinSMEs

Nammi Therapeutics, Inc., a Los Angeles, CA-based immuno-oncology company, received $1M in investment commitment by the Myeloma Investment Fund (MIF).

Myeloma Investment Fund joins Nammi's B round - BioWorld

Nammi Therapeutics Inc. has announced a $1 million investment commitment by the Myeloma Investment Fund (MIF) in a $30 million series B financing round.

Seeding the next wave of myeloma drug development - BioCentury

How the Myeloma Investment Fund approaches venture philanthropy and views the future of the myeloma treatment landscape ... Nammi Therapeutics Inc ...

Multiple Myeloma RF on X: "We're thrilled to announce that the ...

We're thrilled to announce that the Myeloma Investment Fund (MIF) has invested in Nammi Therapeutics, supporting their innovative ...

Portfolio - Myeloma Investment Fund

A clinical-stage cancer immunotherapy company focused on the development and commercialization of novel NK cell therapies that can be infused into patients to ...

Nammi Therapeutics Raises Series B Investment from MMRF's ...

Nammi Therapeutics announces a $1M investment commitment by the Myeloma Investment Fund (MIF) in a $30M Series B financing round.

Series B - Nammi Therapeutics - Crunchbase Funding Round Profile

Myeloma Investment Fund Myeloma Investment Fund is a new, independent, self-sustaining venture fund. Investors.

Myeloma Investment Fund investor portfolio, rounds & team ...

Recent investments ; Triumvira Immunologics ; Indapta Therapeutics ; KAHR Medical ; Fortis Therapeutics ; Nammi Therapeutics.

MMRF Press Releases Archives - Page 2 of 3

Myeloma Investment Fund Invests in Dynamic Cell Therapies to Help Fuel Novel CAR T-Cell Technologies ... Myeloma Investment Fund Invests in Reverb Therapeutics to ...

Nammi Therapeutics doses first subject in trial of QXL138AM for ...

In Part B, the study will expand to dose cohorts with two solid tumour indications and multiple myeloma. The primary endpoints will assess ...

Myeloma Investment Fund® - MIF®

The Myeloma Investment Fund (MIF) invests in companies developing innovative therapies and technologies with potential to transform myeloma patient outcomes.

Nammi Therapeutics - Crunchbase Company Profile & Funding

Who invested in Nammi Therapeutics ? Nammi Therapeutics is funded by Myeloma Investment Fund . How much funding has Nammi Therapeutics raised to date? Nammi ...

Nammi Therapeutics - Valuation, Funding & Investors - PitchBook

Myeloma Investment Fund, California Institute for Regenerative Medicine, and Magnify have invested in Nammi Therapeutics. Data Transparency. Meet our data ...

News - Nammi Therapeutics

Nammi Therapeutics Completes Series B Round with Investment from MMRF's Myeloma Investment Fund. August 6, 2024. Nammi Therapeutics announces a $1M investment ...